Dorzolamide 20 Mg/Ml Eye Drops Solution
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Dorzolamide 20 mg/ml Eye drops, solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains 22.26 mg of dorzolamide hydrochloride corresponding to 20 mg of dorzolamide.
Excipients
Each ml contains 0.075 mg benzalkonium chloride.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Eye drops, solution.
Clear, viscous solution, free from visible particles.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
This medicinal product is indicated:
• As adjunctive therapy to beta-blockers,
• As monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated,
In the treatment of elevated intra-ocular pressure in:
• ocular hypertension,
• open-angle glaucoma,
• pseudo-exfoliative glaucoma.
4.2 Posology and method of administration
When used as monotherapy, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), three times daily.
When used as adjunctive therapy with an ophthalmic beta-blocker, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), two times daily.
When substituting dorzolamide for another ophthalmic anti-glaucoma agent, discontinue the other agent after proper dosing on one day, and start dorzolamide on the next day.
If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.
Patients should be instructed to wash their hands before use and avoid allowing the tip of the container to come into contact with the eye or surrounding structures.
Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Patients should be informed of the correct handling of the bottles.
Usage instructions
1. Before using the medication for the first time, be sure the tamper seal is unbroken.
2. To open the bottle, unscrew the cap.
3. Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and eye.
4. Invert the bottle, and press lightly on the sides of the bottle until a single drop is dispensed into the eye as directed by your doctor. DO NOT TOUCH YOUR EYE OR EYELID WITH THE DROPPER TIP.
5. Repeat steps 3 & 4 with the other eye if instructed to do so by your doctor.
6. Replace the cap by turning until it is firmly touching the bottle.
7. The dispenser tip is designed to provide a pre-measured drop; therefore, do not enlarge the hole of the dispenser tip.
Paediatric use
Limited clinical data in paediatric patients with administration of dorzolamide three times a day are available (for information regarding paediatric dosing see section 5.1).
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients. Dorzolamide has not been studied in patients with severe renal impairment (CrCl < 30 ml/min) or with hyperchloraemic acidosis. Because dorzolamide and its metabolites are excreted predominantly by the kidney, it is therefore contraindicated in such patients.
4.4 Special warnings and precautions for use
Dorzolamide has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients.
The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents.
Dorzolamide has not been studied in patients with acute angle-closure glaucoma.
Dorzolamide contains a sulfonamido group, which also occurs in sulfonamides, and although administered topically, is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulphonamides may occur with topical administration including severe reactions such as Stevens-Johnson necrolysis. If signs of serious reactions of hypersensitivity occur, discontinue the use of this medicinal product.
Therapy with oral carbonic anhydrase inhibitors has been associated with urolithiasis as a result of acid-base disturbances, especially in patients with a prior history of renal calculi. Although no acid-base disturbances have been observed with dorzolamide, urolithiasis has been reported infrequently. Because dorzolamide is a topical carbonic anhydrase inhibitor that is absorbed systemically, patients with a prior history of renal calculi may be at increased risk of urolithiasis while using dorzolamide.
If allergic reactions (eg. conjunctivitis and eyelid reactions) are observed, discontinuation of treatment should be considered.
There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide. The concomitant administration of dorzolamide and oral carbonic anhydrase inhibitors is not recommended.
Corneal oedemas and irreversible corneal decompensations have been reported in patients with pre-existing chronic corneal defects and/or a history of intraocular surgery while using dorzolamide eye drops. Topical dorzolamide should be used with caution in such patients.
Choroidal detachment concomitant with ocular hypotony have been reported after filtration procedures with administration of aqueous suppressant therapies.
This medicinal product contains the preservative benzalkonium chloride, which may cause eye irritation. Contact lenses should be removed prior to application and wait at least 15 minutes before reinsertion. Benzalkonium chloride is known to discolour soft contact lenses.
Paediatric patients
Dorzolamide has not been studied in patients less than 36 weeks gestational age and less than one week of age. Patients with significant renal tubular immaturity should only receive dorzolamide after careful consideration of the risk benefit balance because of the possible risk of metabolic acidosis.
4.5 Interaction with other medicinal products and other forms of interaction
Specific drug interaction studies have not been performed with dorzolamide.
In clinical studies, dorzolamide was used concomitantly with the following products without evidence of adverse interactions: timolol ophthalmic solution, betaxolol ophthalmic solution and systemic products, including angiotensin-converting enzyme (ACE) inhibitors, calcium-channel blockers, diuretics, non-steroidal anti-inflammatory drugs including acetylsalicylic acid, and hormones (e.g. oestrogen, insulin, thyroxine).
Association between dorzolamide and miotics and adrenergic agonists has not been fully evaluated during glaucoma therapy.
4.6 Pregnancy and lactation
Use during pregnancy
Dorzolamide should not be used during pregnancy. No adequate clinical data in exposed pregnancies are available. In rabbits, dorzolamide produced teratogenic effects at maternotoxic doses (see section 5.3).
Use during lactation
It is not known whether dorzolamide is excreted in human milk. In lactating rats, decreases in the body weight gain of offspring were observed. If treatment with dorzolamide is required, then lactation is not recommended.
4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed. Possible side effects such as dizziness and visual disturbances may affect the ability to drive and use machines.
4.8 Undesirable effects
Dorzolamide 2% eye drops solution was evaluated in more than 1,400 individuals in controlled and uncontrolled clinical studies. In long-term studies of 1,108 patients treated with dorzolamide as monotherapy or as adjunctive therapy with an ophthalmic beta-blocker, the most frequent cause of discontinuations from treatment was treatment-related ocular adverse effects in approximately 3% of patients, primarily conjunctivitis and eyelid reactions.
The following adverse reactions have been reported either during clinical trials or during post-marketing experience: [Very common (> 1/10), common (> 1/100, < 1/10), uncommon (> 1/1,000, < 1/100), rare (> 1/10,000, < 1/1,000)]
Nervous system disorders
Common: headache
Rare: dizziness, paraesthesia
Eye disorders Very common: Common:
Uncommon:
Rare:
burning and stinging
superficial punctate keratitis, tearing, conjunctivitis, eyelid inflammation, eye itching, eyelid irritation, blurred vision iridocyclitis
irritation including redness, pain, eyelid crusting, transient myopia (which resolved upon discontinuation of therapy), corneal oedema, ocular hypotony, choroidal detachment following filtration surgery
Respiratory, thoracic and mediastinal disorders Rare: epistaxis
Gastrointestinal disorders
Common: nausea, bitter taste
Rare: throat irritation, dry mouth
Skin and subcutaneous tissue disorders
Rare: contact dermatitis, Stevens-Johnson syndrome, toxic
epidermal necrolysis
Rare:
Renal and urinary disorders urolithiasis
General disorders and administration site conditions Common: asthenia/fatigue
Rare: Hypersensitivity: signs and symptoms of local reactions
(palpebral reactions) and systemic allergic reactions including angioedema, urticaria and pruritus, rash, shortness of breath, rarely bronchospasm
Laboratory _ findings
Dorzolamide was not associated with clinically meaningful electrolyte disturbances.
Paediatric _ patients See section 5.1.
4.9 Overdose
Only limited information is available with regard to human overdose by accidental or deliberate ingestion of dorzolamide hydrochloride.
Symptoms
The following have been reported with oral ingestion: somnolence; topical application: nausea, dizziness, headache, fatigue, abnormal dreams, and dysphagia.
Treatment
Treatment should be symptomatic and supportive. Electrolyte imbalance, development of an acidotic state, and possible central nervous system effects may occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmaco-therapeutic group: Antiglaucoma preparations and miotics, carbonic anhydrase inhibitor ATC code: S01E C03 Mechanism of action
Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II) found primarily in red blood cells (RBCs) but also in other tissues. Inhibition of
carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion. The result is a reduction in intra-ocular pressure (IOP).
Dorzolamide hydrochloride is a potent inhibitor of human carbonic anhydrase II. Following topical ocular administration, dorzolamide reduces elevated intra-ocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and visual-field loss. Dorzolamide does not cause pupillary constriction and reduces intra-ocular pressure without side effects such as night blindness, accommodative spasm. Dorzolamide has minimal or no effect on pulse rate or blood pressure.
Topically applied beta-adrenergic blocking agents also reduce IOP by decreasing aqueous humor secretion but by a different mechanism of action. Studies have shown that when dorzolamide is added to a topical beta-blocker, additional reduction in IOP is observed; this finding is consistent with the reported additive effects of beta-blockers and oral carbonic anhydrase inhibitors.
Pharmacodynamic effects
Clinical effects
Adult patients
In patients with glaucoma or ocular hypertension, the efficacy of dorzolamide given t.i.d. (three times a day) as monotherapy (baseline IOP > 23 mmHg) or given b.i.d. (twice a day) as adjunctive therapy while receiving ophthalmic beta-blockers (baseline IOP > 22 mmHg) was demonstrated in large-scale clinical studies of up to one-year duration. The IOP-lowering effect of dorzolamide as monotherapy and as adjunctive therapy was demonstrated throughout the day and this effect was maintained during long-term administration. Efficacy during long-term monotherapy was similar to betaxolol and slightly less than timolol. When used as adjunctive therapy to ophthalmic beta-blockers, dorzolamide demonstrated additional IOP lowering similar to pilocarpine 2% q.i.d. (four times a day).
Paediatric patients
A three-month, double-masked, active treatment-controlled, multicentre study was undertaken in 184 (122 for dorzolamide) paediatric patients from one week of age to < 6 years of age with glaucoma or elevated intraocular pressure (baseline IOP > 22 mmHg) to assess the safety of dorzolamide when administered topically t.i.d. (three times a day). Approximately half the patients in both treatment groups were diagnosed with congenital glaucoma; other common aetiologies were Sturge Weber syndrome, iridocorneal mesenchymal dysgenesis, aphakic patients. The distribution by age and treatments in the monotherapy phase was as follows:
|
Dorzolamide 2% |
Timolol | |
|
Age cohort < 2 years |
n=56 Age range: 1 to 23 months |
Timolol GS 0.25% n=27 Age range: 0.25 to 22 |
|
months | ||
|
Age cohort > 2 - < 6 years |
n=66 Age range: 2 to 6 years |
Timolol 0.5% n=35 Age range: 2 to 6 years |
Across both age cohorts approximately 70 patients received treatment for at least 61 days and approximately 50 patients received 81-100 days of treatment.
If IOP was inadequately controlled on dorzolamide or timolol gel-forming solution monotherapy, a change was made to open-label therapy according to the following: 30 patients < 2 years were switched to concomitant therapy with timolol gel-forming solution 0.25% daily and dorzolamide 2% t.i.d.; 30 patients > 2 years were switched to 2% dorzolamide/0.5% timolol fixed combination b.i.d. (twice a day).
Overall, this study did not reveal additional safety concerns in paediatric patients:approximately 26% (20% in dorzolamide monotherapy) of paediatric patients were observed to experience treatment-related adverse events, the majority of which were local, non-serious ocular effects such as ocular burning and stinging, injection and eye pain. A small percentage, <4%, were observed to have corneal oedema or haze. Local reactions appeared similar in frequency to comparator.
In post-marketing data, metabolic acidosis in the very young particularly with renal immaturity / impairment has been reported.
Efficacy results in paediatric patients suggest that the mean IOP decrease observed in the dorzolamide group was comparable to the mean IOP decrease observed in the timolol group even if a slight numerical advantage was observed for timolol.
Longer-term efficacy studies (>12 weeks) are not available.
5.2 Pharmacokinetic properties
Unlike oral carbonic anhydrase inhibitors, topical administration of dorzolamide hydrochloride allows for the active substance to exert its effects directly in the eye at substantially lower doses and therefore with less systemic exposure. In clinical trials, this resulted in a reduction in IOP without the acid-base disturbances or alterations in electrolytes characteristic of oral carbonic anhydrase inhibitors.
When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, active substance and metabolite concentrations in red blood cells (RBCs) and plasma and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of selective binding to CA-II while extremely low concentrations of free active substance in plasma are maintained. The parent active substance forms a single A-desethyl metabolite that inhibits CA-II less potently than the parent active substance but also inhibits a less active isoenzyme (CA-I). The metabolite also accumulates in RBCs where it binds primarily to CA-I. Dorzolamide binds moderately to plasma proteins (approximately 33%). Dorzolamide is primarily excreted unchanged in the urine; the metabolite is also excreted in the urine. After dosing ends, dorzolamide washes out of RBCs non-linearly, resulting in a rapid decline of active substance concentration initially, followed by a slower elimination phase with a half-life of about four months.
When dorzolamide was given orally to simulate the maximum systemic exposure after long-term topical ocular administration, steady-state was reached within 13 weeks. At steady-state, there was virtually no free active substance or metabolite in plasma; CA inhibition in RBCs was less than that anticipated to be necessary for a pharmacological effect on renal function or respiration. Similar pharmacokinetic results were observed after chronic topical administration of dorzolamide
However, some elderly patients with renal impairment (estimated CrCl 30-60 ml/min) had higher metabolite concentrations in RBCs, but no meaningful differences in carbonic anhydrase inhibition, and no clinically significant systemic adverse effects were directly attributable to this finding.
5.3 Preclinical safety data
The main findings in animal studies with dorzolamide hydrochloride administered orally were related to the pharmacological effects of systemic carbonic anhydrase inhibition. Some of these findings were species-specific and/or were a result of metabolic acidosis. In rabbits given maternotoxic doses of dorzolamide associated with metabolic acidosis, malformations of the vertebral bodies were observed.
In clinical studies, patients did not develop signs of metabolic acidosis or serum electrolyte changes that are indicative of systemic CA inhibition. Therefore, it is not expected that the effects noted in animal studies would be observed in patients receiving therapeutic doses of dorzolamide.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Hydroxyethyl cellulose
Mannitol E421 Sodium citrate E331
Sodium hydroxide E524 (to adjust to an approximate pH of 5.6) Benzalkonium chloride Water for injection
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
2 years
After first opening: 28 days maximum
6.4 Special precautions for storage
Store below 30°C.
Do not refrigerate or freeze.
6.5 Nature and contents of container
Dorzolamide 2% Eye drops solution is filled into a 5 ml fill volume capacity polyethylene bottle equipped with a dropper applicator and closed with a tamper proof cap.
Pack sizes:
1 x 5 ml (single 5 ml bottle)
3 x 5 ml (three 5 ml bottle)
6 x 5 ml (six 5 ml bottle)
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements.
See section 4.2 for patient instructions.
7 MARKETING AUTHORISATION HOLDER
Teva UK Limited, Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG
8 MARKETING AUTHORISATION NUMBER(S)
PL 00289/1116
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
31/01/2011
10 DATE OF REVISION OF THE TEXT
31/01/2011